Serum Alcohol Dehydrogenase and Aldehyde Dehydrogenase Activity in the Course of Hepatitis C

Clinical Laboratory
|February 7, 2017
PubMed

Insights

Hepatitis C patients show significantly increased levels of alcohol dehydrogenase (ADH) isoenzymes I and II in their serum. This elevation in ADH activity is linked to liver cell damage caused by the Hepatitis C virus (HCV).

Area of Science:

  • Hepatology
  • Clinical Biochemistry
  • Virology

Background:

  • Hepatitis C virus (HCV) infection impacts 170 million globally, a primary cause of chronic liver disease.
  • Liver cell damage in HCV is indicated by elevated serum enzyme activities, including alcohol dehydrogenase (ADH) and aldehyde dehydrogenase (ALDH).
  • ADH and ALDH are crucial for metabolizing various substances and are predominantly found in the liver.

Purpose of the Study:

  • To investigate alcohol dehydrogenase (ADH) activity and its isoenzymes in hepatitis C patients.
  • To assess the total aldehyde dehydrogenase (ALDH) activity in the serum of individuals with hepatitis C.

Main Methods:

  • Serum samples from 50 hepatitis C patients and 50 healthy controls were analyzed.
  • Spectrofluorometric methods measured ADH isoenzymes I and II, and total ALDH activity.
  • Photometric methods determined total ADH activity and ADH isoenzymes III and IV.

Main Results:

  • A statistically significant 2.5-fold increase in ADH I and a 2-fold increase in ADH II activity were observed in hepatitis C patients.
  • Elevated ADH isoenzyme activities correlated well with alanine and aspartate aminotransferase levels.
  • Total ADH activity showed a moderate increase, confirming the heightened activity of ADH classes I and II.

Conclusions:

  • Class I and II alcohol dehydrogenase isoenzymes are significantly elevated in the serum of hepatitis C patients.
  • This increase is likely due to the release of these enzymes from liver cells damaged by the Hepatitis C virus.
Abstract

Related Concept Videos

Enzyme Inhibition01:30

Enzyme Inhibition

Inhibitors are molecules that reduce enzyme activity by binding to the enzyme. In a normally functioning cell, enzymes are regulated by a variety of inhibitors. Drugs and other toxins can also inhibit enzymes. Some inhibitors bind to the enzyme’s active site, while others inhibit enzymatic activity by binding to other sites on the protein structure.
94.3K
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test01:22

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test

In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess...
245
NMR Spectroscopy and Mass Spectrometry of Aldehydes and Ketones01:15

NMR Spectroscopy and Mass Spectrometry of Aldehydes and Ketones

In aldehydes, the hydrogen atom connected to the carbonyl carbon helps distinguish aldehydes from other carbonyl compounds using ¹H NMR spectroscopy. The closeness of aldehydic hydrogen to the electrophilic carbonyl carbon highly deshields the hydrogen atom causing its signal to appear around 10 ppm in the ¹H NMR spectra. α hydrogens split the aldehydic proton signal, which helps identify the number of α hydrogens in the molecule. For instance, one α hydrogen creates a...
5.9K
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow01:26

Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow

Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug...
304